Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled preprandial human insulin (AERx iDMS) versus subcutaneous insulin aspart in diabetic patients with asthma
2006-004622-81Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- Apr 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human insulin in diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM) and asthma (2 arms), sponsored by Novo Nordisk. Primary endpoints: Change in FEV1 (% predicted), Change in FVC (% predicted) and 4 more. Started Apr 2008; status: terminated.
02
Drugs
human insulin
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)asthma
Beyond the preview
Go deeper on 2006-004622-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004622-81.